Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Q32 Bio Inc.

NASDAQ: QTTB · Life Sciences · 6 alerts · CIK 1661998

Share price
$8.29Close, Nov 16
Market cap
$248M
Shares outstanding
29.92MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Q32 Bio Inc. filings on SEC EDGAR ↗

9:20 AM ET 8-K
Clinical Trial Data

Q32 Bio Clinical Trial Data

Q32 Bio presented additional 36-week results and initial 16-week off-drug findings from its SIGNAL-AA Phase 2a trial of bempikibart in patients with severe alopecia areata. The data showed clinically meaningful efficacy, including a 35.3% mean reduction in SALT scores, and supported the drug's advancement into a registration-directed program in the first half of 2027.

“Bempikibart’s robust efficacy data and durability observed across the 36-week treatment period and 16-week off-drug period in both JAK inhibitor-experienced and JAK inhibitor-naïve patients, changes on biomarkers supportive of its bifunctional mechanism, and its favorable safety and tolerability profile support its continued development in a registration-directed program in patients with severe or very severe alopecia areata as well as in expanded alopecia areata populations and other autoimmune and inflammatory indications.”

Jodie Morrison, Chief Executive Officer of Q32 Bio

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.